(1/3)(1/3)

,, ,, , , , ,

(( ))

--

: 15: 15--30 30 , , , , . . . .

IN SITU IN SITU (() ) : 5: 5--10 10 , ,

: 1: 1--5 5 , , . .

: :

stagingstaging 0: 0: in situin situ :: : :

: :

VV: : : :

, , ((grade), grade), , ,

((, , PCR)PCR)

CaCa . . CEACEA CaCa ER, ER,

CA15.3,Her2neuCA15.3,Her2neu

CaCa PSAPSA CaCa CA125,CA19.9CA125,CA19.9 CaCa CaCa AFP,AFP,hCGhCG XX

SS--100B100B , ,

XX

(( CA15CA15--3,CA193,CA19--9, CA1259, CA125))

(( CEA,AFP,CEA,AFP,hCG)hCG)

(PSA,(PSA, LDH)LDH) (( )) (HCG, ER, PrgR)(HCG, ER, PrgR) (IL(IL--2,IL4)2,IL4)

(IgG (IgG )) (())

(( )) ((,,

ICAM)ICAM) (BRCA(BRCA--1, 1, p53)p53)

(())--

((Ca125Ca125 CA CA , , , , , , CEACEA , , ))

11--5% 5%

CEACEA ((, , , , , , ))

((, , , , , , , , ) )

((, , , , , , ))

PSAPSA

: : 15 15 , , CACA

PSA PSA

, ,

PSAPSA

PSA PSA CA CA

Free PSA / Total PSAFree PSA / Total PSA Free PSA / Total PSAFree PSA / Total PSA

CACA

CEA, AFPCEA, AFP

CEACEA

CEACEA 55--10 10 ng/ml ng/ml >20 >20 ng/ml ng/ml CACA (2(2x), x), , , , , , , , ,

CACA (( ))

CACA , , , , , , , , , , CACA 1919--9, 9, CACA125 125

AFPAFP ((, , ))

3030 250250--300 300 ng/ml ng/ml CA CA

< 10 < 10 ng/ml ng/ml

HCGHCG

--

-- ..

Overview of Proteomic Approach

Numbers of publications on biomarkers and Numbers of publications on biomarkers and FDA approval of biomarkers.FDA approval of biomarkers.